| Identification | Back Directory | [Name]
Acapatamab | [CAS]
2314491-93-3 | [Synonyms]
Acapatamab
Research Grade Acapatamab
Research Grade Acapatamab (DHG01305) |
| Hazard Information | Back Directory | [Uses]
Acapatamab (AMG-160) is an anti-CD3E/FOLH1 monoclonal antibody[1]. | [in vivo]
Acapatamab (0.02-2 mg/kg; i.v.; days 16, 23, and 31) has antitumor activity and inhibits tumor growth in NOD/SCID mice with 22Rv-1 CRPC xenografts[1]. | Animal Model: | NOD/SCID mice with 22Rv-1 CRPC xenografts[1] | | Dosage: | 0.02, 0.2, and 2 mg/kg | | Administration: | Intravenous injection (days 16, 23, and 31) | | Result: | Had antitumor activity against established CRPC tumors. |
| [References]
[1] Acapatamab |
|
| Company Name: |
Biolab Reagents
|
| Tel: |
65279366 18108604356 |
| Website: |
www.biolabreagent.com/ |
| Company Name: |
Cell Sciences
|
| Tel: |
9785721070 |
| Website: |
www.cellsciences.com |
|